Equities

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Actions
  • Price (EUR)0.87
  • Today's Change-0.045 / -4.92%
  • Shares traded3.50k
  • 1 Year change+30.83%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Adaptimmune Therapeutics PLC grew revenues 122.05% from 27.15m to 60.28m while net income improved from a loss of 165.46m to a smaller loss of 113.87m.
Gross margin--
Net profit margin-51.25%
Operating margin-54.54%
Return on assets-21.81%
Return on equity-65.04%
Return on investment-28.63%
More ▼

Cash flow in USDView more

In 2023, Adaptimmune Therapeutics PLC increased its cash reserves by 34.14%, or 37.42m. Cash Flow from Investing totalled 176.54m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 140.88m for operations while cash generated from financing totalled 880.00k.
Cash flow per share-0.2561
Price/Cash flow per share--
Book value per share0.3765
Tangible book value per share0.3726
More ▼

Balance sheet in USDView more

Adaptimmune Therapeutics PLC has a Debt to Total Capital ratio of 20.58%.
Current ratio3.09
Quick ratio--
Total debt/total equity0.2592
Total debt/total capital0.2058
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.